Bank of America just raised its EUR/USD forecast
REDWOOD CITY, Calif. - Corcept Therapeutics Incorporated (NASDAQ: CORT), which has delivered an impressive 157% return to investors over the past year and maintains a robust 98.36% gross profit margin, announced results from its Phase 3 ROSELLA trial, suggesting that relacorilant combined with nab-paclitaxel could be an effective treatment for patients with platinum-resistant ovarian cancer. These findings were presented at the ASCO 2025 Annual Meeting and concurrently published in The Lancet.
The ROSELLA trial met its primary endpoint, demonstrating that patients treated with the combination therapy had a 30% lower risk of disease progression compared to those who received nab-paclitaxel alone. The median progression-free survival improved to 6.5 months from 5.5 months. Additionally, an interim analysis indicated a 31% reduction in the risk of death, with median overall survival extending to 16.0 months from 11.5 months. According to InvestingPro analysis, Corcept is currently trading above its Fair Value, with analysts setting price targets between $131 and $145.
The study involved 381 patients across multiple global sites and did not require biomarker selection. The combination therapy also showed a well-tolerated safety profile, without increasing the side-effects compared to monotherapy. Notably, patients on the relacorilant and nab-paclitaxel regimen experienced lower incidences of ascites and required fewer abdominal paracenteses.
Dr. Alexander B. Olawaiye, the ROSELLA trial’s Principal Investigator, stated that the data support this treatment becoming a new standard of care for patients with platinum-resistant ovarian cancer, a condition with limited treatment options once it becomes resistant to chemotherapy.
Corcept’s Chief Development Officer, Bill Guyer, PharmD, remarked on the potential of relacorilant to help patients live longer without adding to their safety burden. The company, which has shown strong revenue growth of 30.93% over the last twelve months and maintains a healthy financial position with a current ratio of 3.07, is expediting regulatory applications in the U.S. and Europe to make this treatment available to patients. InvestingPro subscribers can access 15+ additional investment tips and comprehensive financial analysis for Corcept in the Pro Research Report, helping investors make informed decisions about this rapidly growing biotech company.
Relacorilant, an oral selective glucocorticoid receptor antagonist, is being studied for various serious disorders, including Cushing’s syndrome and prostate cancer. It has received orphan drug designation for the treatment of hypercortisolism and ovarian cancer.
Corcept Therapeutics focuses on cortisol modulation to treat severe disorders. The company has developed a portfolio of selective cortisol modulators, conducting advanced clinical trials in multiple diseases. Corcept introduced Korlym in 2012, the first FDA-approved medication for patients with endogenous hypercortisolism.
This news article is based on a press release statement from Corcept Therapeutics.
In other recent news, Corcept Therapeutics reported its first-quarter earnings for 2025, revealing an earnings per share (EPS) of $0.17, which exceeded analysts’ expectations of $0.14. However, the company’s revenue came in at $157.2 million, falling short of the anticipated $177.9 million. Corcept’s management has maintained their revenue guidance for 2025, projecting sales between $900 million and $950 million, despite the revenue miss. Piper Sandler has reiterated its Overweight rating on Corcept’s stock with a price target of $131, while H.C. Wainwright adjusted its price target to $145 from $150 but maintained a Buy rating. The company faced challenges with its pharmacy vendor, which affected the first-quarter results, but improvements have been made since March. The transition to an authorized generic version of Korlym led to a 13% decrease in the average price per tablet, yet the number of prescriptions nearly doubled compared to the previous year. Analysts from Piper Sandler and H.C. Wainwright see potential growth opportunities for Corcept, particularly with relacorilant, which is under FDA review for treating hypercortisolism and platinum-resistant ovarian cancer. The New Drug Application for relacorilant has been filed, with a decision expected by December 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.